BIIB Stock Movement Summary Biogen reported fourth-quarter 2025 earnings on Friday that exceeded expectations, causing the stock to surge approximately 9%. The company reported adjusted EPS of $1.99, beating the consensus estimate of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion. Key earnings details include: - Multiple sclerosis treatment revenue declined double-digits - Alzheimer's drug Leqembi sales jumped significantly - Fiscal 2025 growth products revenue increased 19% year-over-year, offsetting MS declines - The company swung to a loss in Q4 due to MS revenue decline Following the Friday surge, the stock subsequently gave back a portion of gains as profit-taking occurred. Analysts maintained positive outlooks, with Baird reiterating an Outperform rating and $250 price target, and Oppenheimer raising its target to $250.
Read full analysisBIIB Stock Movement Summary Biogen reported fourth-quarter 2025 earnings on Friday that exceeded expectations, causing the stock to surge approximately 9%. The company reported adjusted EPS of $1.99, beating the consensus estimate of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion. Key earnings details include: - Multiple sclerosis treatment revenue declined double-digits - Alzheimer's drug Leqembi sales jumped significantly - Fiscal 2025 growth products revenue increased 19% year-over-year, offsetting MS declines - The company swung to a loss in Q4 due to MS revenue decline Following the Friday surge, the stock subsequently gave back a portion of gains as profit-taking occurred. Analysts maintained positive outlooks, with Baird reiterating an Outperform rating and $250 price target, and Oppenheimer raising its target to $250.
Biogen Inc (BIIB) is a publicly traded company in the Healthcare sector.